secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001104659-24-069625
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CARA shareholders approve doubling authorized shares and authorize reverse stock split
--------------------------------------------------------------------------------

- Authorized common stock increased from 100M to 200M shares; 76.5% of votes in favor.
- Board authorized to implement reverse stock split at ratio 1:4 to 1:12, with proportionate reduction in authorized shares.
- Directors Susan Shiff and Helen Boudreau elected; advisory say-on-pay passed with 16.3M for vs 10.7M against.
- Ernst & Young ratified as independent auditor for FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924069625/0001104659-24-069625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924069625/tm2416682d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-069625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer